Trial of Anifrolumab in Active Systemic Lupus ErythematosusEric F. Morand, Raj Tummala, Richard Furie et al.|New England Journal of Medicine|2019Cited by 1.3k
EULAR recommendations for the management of systemic lupus erythematosus: 2023 updateAntonis Fanouriakis, Dimitrios T. Boumpas, Richard Furie et al.|Annals of the Rheumatic Diseases|2023Cited by 913
The immune cell landscape in kidneys of patients with lupus nephritisBetty Diamond, Arnon Arazi, Deepak A. Rao et al.|Nature Immunology|2019Cited by 840
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trialRichard Furie, Raj Tummala, Eric F. Morand et al.|The Lancet Rheumatology|2019Cited by 478
A Randomized, <scp>Placebo‐Controlled</scp> Phase <scp>III</scp> Extension Trial of the <scp>Long‐Term</scp> Safety and Tolerability of Anifrolumab in Active Systemic Lupus ErythematosusKenneth Kalunian, Hussein Al‐Mossawi, Richard Furie et al.|Arthritis & Rheumatology|2022Cited by 151